National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Obinutuzumab (Gazyvaro®) in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.

Rapid Review Process Complete
Rapid review received 08/08/2017
Rapid review completed 13/09/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended